在高血压患者中,AT1R基因的rs389566多态性有助于MACCEs
Jun-Yi Luo1,2, Guo-Li Du1,3, Yang-Min Hao3
1State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Urumqi, China.
BMC cardiovascular disorders
|June 3, 2023
概括
在高血压患者中,AT1R基因rs389566 TT基因型与较高心血管和脑血管重大不良事件 (MACCEs) 风险有关. 这一发现凸显了针对这种遗传倾向的个体需要有针对性的预防策略.
科学领域:
- 心血管遗传学 心血管遗传学
- 高血压研究 高血压研究
- 药物基因组学 药物基因组学
背景情况:
- 高血压是心血管和脑血管事件的主要危险因素.
- 遗传多态性,例如在血管激素II受体1型 (AT1R) 基因中,可能会影响个体对这些事件的易感性.
- 了解这些关联可以帮助个性化风险评估和管理.
研究的目的:
- 调查AT1R基因多态化与主要心血管和脑血管不良事件 (MACCEs) 之间的关联.
- 为了评估新疆高血压患者的这种关联,有或没有冠状动脉疾病 (CAD).
主要方法:
- 在374名CAD患者和341名非CAD高血压患者中,使用SNPscanTM类型分析对AT1R基因多态的基因定型.
- 后续评估以记录MACCEs.
- 卡普兰-梅尔曲线和考克斯生存分析以确定关联.
主要成果:
- AT1R基因rs389566的多态性与MACCEs有显著的关联.
- 与AA + AT基因型 (24.8%,P=0.033) 相比,rs389566的TT基因型显示MACCE的可能性更高 (75.2%).
- 老年 (OR=1.028) 和rs389566 TT基因型 (OR=1.770) 被确定为MACCEs的独立风险因素.
结论:
- AT1R基因rs389566 TT基因型可能使高血压患者易患MACCEs.
- 在患有CAD的高血压患者中,特别是在患有rs389566 TT基因型的老年人中,应特别注意预防MACCE.
- 改变生活方式,控制血压以及对遗传风险因素的认识对于减少MACCE至关重要.
更多相关视频
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
11.9K
09:37A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
8.3K
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
790
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
790
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
470
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
470
01:30Coronary Artery Disease I: Introduction
33
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
33
01:17Antihypertensive Drugs: Action of β1 Blockers
492
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
492
01:25Antihypertensive Drugs: Direct Renin Inhibitors
711
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
711
01:26Adrenergic Receptors: β Subtype
1.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.8K